CCM
EWTX icon

CAAS Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

CAAS Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$975K – 1113
2021
Q1 		$975K Buy
+30,000
New +$973K 0.01% 810

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAAS Capital Management's EWTX Position: Q2 2021 in Review

CAAS Capital Management sold out of Edgewise Therapeutics (EWTX) in Q2 2021, closing a stake of 30,000 shares — an estimated $975K sold.

CAAS Capital Management first reported a position in EWTX in Q1 2021 and held it in 1 quarter. The position peaked at $975K in Q1 2021. 46 funds tracked by Wall St. Rank hold EWTX as of Q2 2021.

  • CAAS Capital Management reported no remaining Edgewise Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 30,000 Edgewise Therapeutics shares in Q2 2021, an estimated $975K.
  • CAAS Capital Management first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Edgewise Therapeutics position peaked at $975K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.